

Review

Open Access



# Cost-effectiveness of colonoscopy and related procedures: population screening perspectives

Wen-Feng Hsu, Han-Mo Chiu

Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.

**Correspondence to:** Han-Mo Chiu, Department of Internal Medicine, College of Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. E-mail: hanmochiu@ntu.edu.tw

**How to cite this article:** Hsu WF, Chiu HM. Cost-effectiveness of colonoscopy and related procedures: population screening perspectives. *Mini-invasive Surg* 2022;6:26. <https://dx.doi.org/10.20517/2574-1225.2022.03>

**Received:** 1 Feb 2022 **First Decision:** 10 Mar 2022 **Revised:** 27 Mar 2022 **Accepted:** 6 Apr 2022 **Published:** 9 May 2022

**Academic Editor:** Giulio Belli **Copy Editor:** Jia-Xin Zhang **Production Editor:** Jia-Xin Zhang

## Abstract

Colorectal cancer (CRC) screening can reduce the incidence and mortality of CRC, and many countries with moderate-to-high incidences of CRC have implemented population screening programs. Colonoscopy plays a pivotal role in the context of CRC screening as the primary screening modality, the diagnostic exam after a positive noninvasive test, the therapeutic procedure for resecting detected neoplasms, and the surveillance exam after the removal of neoplastic lesions. Although colonoscopy outperforms other noninvasive tests in detecting colorectal neoplasms, it is associated with higher cost, manpower, and invasiveness. Owing to the heterogeneity of healthcare systems in terms of the scale of health revenue, population demographics, and the payment systems in each country, the optimal or most cost-effective screening strategy may vary. Accordingly, economic appraisal of different approaches is essential, especially in organized screening programs within which the resources and the clinical capacity are constrained, and each step of the screening flow needs careful monitoring. The therapeutic procedures applied to manage screening-detected lesions and subsequent surveillance procedures also contribute to substantial additional costs. The level of willingness to pay is affected by various factors, including demographics, income, educational level, and health consciousness, and largely affects the optimal strategies. Herein, we systematically review and summarize the current evidence regarding the cost-effectiveness of colonoscopic screening, related therapeutic procedures, and subsequent surveillance and provide a balanced view from the perspective of population screening programs. It was revealed that 10-year colonoscopy is the most effective strategy compared to other strategies under the higher willingness-to-pay threshold or low colonoscopy cost. There are, however, discrepancies in the results among studies from different countries, which could be associated with the different cost parameters and assumptions used in the models. As for various therapeutic procedures for colorectal neoplasms such as polypectomy, endoscopic mucosal resection, or endoscopic



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



submucosal dissection, strategies based on the risk of advanced histology or deep submucosal invasion based on image-enhanced endoscopy are the least expensive and avoid more recurrences. Furthermore, subsequent surveillance strategies that are based on the risk of CRC are more cost-effective. This article provides a comprehensive review of the literatures and a balanced view from the perspective of population screening programs.

**Keywords:** Colonoscopy, cost-effectiveness, colorectal cancer screening, surveillance, polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection

## INTRODUCTION

Colorectal cancer (CRC) is the second most common cancer in women and the third most common cancer in men worldwide<sup>[1]</sup>. Early detection of CRC by effective screening strategies and removal of screening-detected adenomatous polyps is the most effective way to reduce the mortality associated with an incidence of CRC<sup>[2]</sup>. Colonoscopy is the essential process and common pathway of CRC screening and plays a pivotal role in a screening program. Furthermore, patients who have adenomas detected during a colonoscopy are at increased future risk of CRC even after removal of the lesions; therefore, periodic surveillance is indispensable for providing further protection against metachronous CRC<sup>[3,4]</sup>. The major guidelines currently recommend surveillance intervals based primarily on colonoscopic findings and place special emphasis on the number, size, and histology of detected neoplasms<sup>[5-7]</sup>. Along with the increasing CRC epidemiology and the launch of population CRC screening in many developed countries, colonoscopy has nowadays become one of the most frequently performed clinical procedures<sup>[8]</sup>; colonoscopies have become a dominant workload, and the costs of colonoscopies and their related procedures have become a significant financial burden for healthcare systems<sup>[9]</sup>. The majority of colonic lesions detected by screening, however, are asymptomatic precancerous lesions and early CRCs; thus, subsequent treatment costs could be saved compared with that in the symptomatic clinical stage. Hence, there is a trade-off between the costs of colonoscopies and their related procedures and the treatment of colonic lesions including CRCs. Evolving endoscopic technologies such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) provide less invasive curative treatment options. The appropriate position of ESD in clinical practice is worthy of consideration. In general, ESD is more costly than the traditional polypectomy or EMR, but the expense is much lower than surgery and related expenses (admission fee, anesthesia, *etc.*). If compared with conventional polypectomy or EMR, it can reduce local recurrence or even post-colonoscopy colorectal cancer (PCCRC); and, if compared with surgery, it can reduce post-treatment morbidity, shorten the duration of admission, and improve the quality of life of the patients. These therapeutic options should be precisely tailored to appropriate lesions that would benefit from individual treatment, thereby balancing effectiveness (PCCRC and CRC mortality), cost, and willingness-to-pay (WTP) levels.

From the population screening perspective, screening logistics involve multiple steps, and each incurs various expenditures. Colonoscopy is the costliest part of the entire screening program, even when considering its related procedures. In this article, we systematically review the current evidence regarding economic appraisals pertaining to colonoscopic screening, therapeutic procedures for screening-detected neoplasms, and subsequent surveillance and provide a balanced view from the perspective of population screening programs.

## METHODS

We conducted this systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines<sup>[10]</sup> and Cochrane Handbook for systematic reviews<sup>[11]</sup>. We conducted an electronic search on PubMed and Cochrane databases using the following terms: colonoscopy; colorectal cancer; cost-effectiveness; colorectal cancer screening; surveillance; polypectomy; resect-and-discard; endoscopic mucosal resection; endoscopic submucosal dissection. Our search was restricted to studies written in English and published between January 2012 and December 2021. The titles and abstracts were screened by W.F.H. and H.M.C. to exclude irrelevant studies. The full articles of potentially eligible studies were further reviewed by W.F.H. and H.M.C. independently.

## DECISION ANALYSES AND ECONOMIC APPRAISALS OF DIFFERENT CRC SCREENING STRATEGIES: COLONOSCOPY VS. VARIOUS NONINVASIVE TESTS

Many previous studies have investigated the economic impact of various CRC screening strategies<sup>[12,13]</sup>. There are two main CRC screening methods: direct colonoscopy and two-tier noninvasive screening strategies using stool tests, such as guaiac fecal occult blood tests, fecal immunochemical test (FIT), or stool DNA tests, as the primary screening test followed by colonoscopy if positive test results are obtained. Colonoscopy has a higher ability to detect colonic neoplasms, especially early-stage CRC or precancerous neoplasms, than other noninvasive tests but is associated with higher risk and related costs<sup>[14]</sup>. Moreover, the effectiveness of CRC screening may be offset by the lower participation rate<sup>[14]</sup>. In addition to colonoscopy, there are several other noninvasive modalities for CRC screening, and these modalities decrease the demand for colonoscopic capacity, hence reducing the incidence of colonoscopy-related complications. Although those modalities may enhance screening participation rate, their ability to detect adenoma and early CRC is inferior to colonoscopy. Eleven studies analyzed the cost-effectiveness of different screening strategies [Table 1]<sup>[15-26]</sup>. Compared with no screening strategy, screening with a 10-year colonoscopy was cost-saving in four studies<sup>[16,19,21,23]</sup> and was cost-effective in the other seven studies<sup>[15,17,18,20,22,24,26]</sup>.

The two-tier screening strategy with the FIT as the primary screening test is currently the most preferred way of providing CRC screening service in regions or countries where endoscopy capacity is constrained. It has nowadays become the mainstay of the stool-based screening approach, as it has the advantage of absolving the need for dietary restriction, has a more user-friendly platform with higher screening participation by the public, and provides higher test performance compared with that of guaiac FOBT<sup>[27]</sup>. When 10-year colonoscopy was compared with FIT screening strategies (annual/biennial), two studies from the United States reported that colonoscopy screening had an incremental cost-effectiveness ratio (ICER) below \$50,000/per quality-adjusted life-year (QALY) and was dominant with 100% certainty<sup>[16,25]</sup>. Six other studies showed that colonoscopy every 10 years was more costly but with more life-years (LYs)/QALYs gained; hence, it was more cost-effective than the annual FIT screening strategy<sup>[15,18,19,23,24,26]</sup>. Four studies reported that annual FIT screening was more effective and less costly than 10-year colonoscopy<sup>[17,20,21,24]</sup>. The results mainly indicate that adherence to the noninvasive screening tests was presumed to be higher than that to the colonoscopy. In two studies, when 10-year colonoscopy was compared with biennial FIT, the former was less cost-effective, and the ICER was higher than \$200,000/per LY/QALY<sup>[17,24]</sup>. One study from Hong Kong reported that biennial FIT was less costly and more effective than colonoscopy every 10 years under the assumption of the same compliance rate of 60% for all screening strategies<sup>[22]</sup>. Some studies also assessed mixed-method screening with combined FIT and colonoscopy or sigmoidoscopy. In the analysis conducted by Dinh and colleagues, colonoscopy every 10 years was more cost-effective than initial annual FIT/colonoscopy screening once and subsequent annual FIT/sigmoidoscopy screening and had ICERs of \$35,000 and \$51,000 per QALY gained, respectively<sup>[19]</sup>. In Ladabaum's study, hybrid strategies with biennial FIT and colonoscopy had greater effectiveness and lower costs than 10-year colonoscopy<sup>[21]</sup>.

**Table 1. Overview of cost-effectiveness analyses on different strategies of CRC screening**

Study	Model type	Country	Effectiveness	Adherence rate, %	Screening age, y	Screening strategies	Cost \$/per person	LY/QALY	ICER vs. colonoscopy	Optimal strategy at different willingness-to-pay thresholds		
										\$20,000/LYG	\$50,000/LYG	\$100,000/LYG
Telford <i>et al.</i> [15], 2010	Markov model	Canada	QALY	73	50-75	10-year colonoscopy	1529	15.32	Reference	Colonoscopy	Colonoscopy	Colonoscopy
						No screening	783	15.20	6216.67			
						Annual gFOBt	1415	15.26	1900.00			
						Annual FIT	1437	15.30	4600.00			
Knudsen <i>et al.</i> [16], 2010	Microsimulation: MISCAN/SimCRC/CRC-SPIN	US	LY	100	65-80	10-year colonoscopy	MISCAN:3840 SimCRC:2680 CRC-SPIN:1980	MISCAN:0.1516 SimCRC:0.1713 CRC-SPIN:0.1849	Reference	Colonoscopy	Colonoscopy	Colonoscopy
						No screening	MISCAN:4030 SimCRC:3540 CRC-SPIN:3000	MISCAN:0 SimCRC:0 CRC-SPIN:0	MISCAN: Dominated SimCRC: Dominated CRC-SPIN: Dominated			
						Annual FIT	MISCAN:3820 SimCRC:2750 CRC-SPIN:2110	MISCAN:0.1410 SimCRC:0.1483 CRC-SPIN:0.1504	MISCAN:1886 SimCRC: Dominated CRC-SPIN: Dominated			
						5-year CTC: DoD	MISCAN:4540 SimCRC:3280 CRC-SPIN:2650	MISCAN:0.1495 SimCRC:0.1682 CRC-SPIN:0.1777	MISCAN: Dominated SimCRC: Dominated CRC-SPIN: Dominated			
						5-year CTC: NCTC every 5 years	MISCAN:4590 SimCRC:3350 CRC-SPIN:2700	MISCAN:0.1427 SimCRC:0.1602 CRC-SPIN:0.1722	MISCAN: Dominated SimCRC: Dominated CRC-SPIN: Dominated			
Hassan <i>et al.</i> [17], 2011*	Markov model	France	LY	40	50-75	10-yearly colonoscopy	1474.73	0.04754	Reference	Biennial FIT	Biennial FIT	Annual FIT
						No screening	885.56	0	12393			
						Annual gFOBt	995.89	0.03994	63005			
						Biennial gFOBt	896.76	0.03201	37216			
						Annual FIT	1227.76	0.04908	-160370			

						Biennial FIT	1026.62	0.04538	207458			
						5-year FS	1117.86	0.04517	150578			
						10-year FS	995.96	0.03705	45640			
						5-year CCE	2022.64	0.04901	372727			
						10-year CCE	1493.90	0.04341	Dominated			
Dan <i>et al.</i> <sup>[18]</sup> , 2012	Markov model	Singapore	QALY	50	50-75	10-year colonoscopy	819	16.406*	Reference	Single sigmoidoscopy	FIT	Colonoscopy
						No screening	219	16.389*	35294.118			
						Annual FIT	345	16.393*	36461.538			
						5-year FS	426	16.394*	32750			
						5-year FS +annual FIT	520	16.396*	29900			
						5-year Stool DNA	560	16.396*	25900			
						5-year CTC	1086	16.406*	Dominated			
						Hybrid: FIT+ colonoscopy	610	16.404*	104500			
Dinh <i>et al.</i> <sup>[19]</sup> , 2013	Microsimulation	US	QALY	100	50-75	10-year colonoscopy	2082	15.79*	Reference	Annual FIT	Annual FIT/Colonoscopy x1	Concurrent FIT/FS
						No screening	3197	15.675*	Dominated			
						Annual FIT	1771	15.771*	16368			
						Annual FIT/colonoscopy x1	1907	15.785*	35000			
						Concurrent FIT/FS	1929	15.787*	51000			
						FS	2118	15.746*	Dominated			
Sharaf and Ladabaum <sup>[20]</sup> , 2013	Markov model	US	QALY	100	50-80	10-year colonoscopy	2564	18.7443*	-			
						No screening	2364	18.6686*	2642			
						Annual FOBT	1953	18.7352*	67142			
						Annual FIT	1866	18.7456*	-536923			
						Annual FIT + 5-year FS	2225	18.7469*	-130384			
						5-yearly FS	2160	18.7372*	56901			
Ladabaum <i>et al.</i> <sup>[21]</sup> , 2014*	Markov model	Germany	QALY	100	50-75	10-year colonoscopy for subjects 55-65	1296.11	19.6715*	Reference	FIT	FIT/Colonoscopy 55-65 years	

Author	Model	Country	QALY	Age	Intervention	QALY			Reference	Comparison 1	Comparison 2		
						QALY	QALY	QALY					
Wong <i>et al.</i> [22], 2015	Markov model	Hong Kong	LY, QALY	60	50-75	years							
						No screening	2585.4	19.5815*	Dominated				
						10-year colonoscopy for subjects 60-70 years	1350.35	19.6524*	Dominated				
						FIT	1185.37	19.6832*	-9464.96				
						FIT /colonoscopy 55-65 years	1240.74	19.6872*	-3526.75				
						FIT /colonoscopy 60-70 years	1186.5	19.6822*	-10243.93				
						Biennial <sup>m</sup> SEPT9-2well	2636.29	19.6531*	Dominated				
						Biennial <sup>m</sup> SEPT9-3well q2	2398.99	19.6645*	Dominated				
						Annual <sup>m</sup> SEPT9-2well	2954.95	19.6732*	975788.24				
						Annual <sup>m</sup> SEPT9-3well	2670.19	19.6797*	167570.73				
Sekiguchi <i>et al.</i> [23], 2016 **	Markov model	Japan	QALY	60	40+	10-year colonoscopy	4752	15.7385/15.3586	Reference	No-screening	Annual FIT	Annual FIT	
						No screening	2541	15.6420/14.7479	22911.92				
						Annual gFOBt	5349	15.7104/15.2339	Dominated				
						Biennial gFOBt	4221	15.6862/15.0687	10152.96				
						Annual FIT	5068	15.7650/15.5491	11924.53				
	Biennial FIT	4542	15.7429/15.4206	-47727.27									
	Markov model	US	QALY		100	50-80	10-year colonoscopy	879.384	23.1778*	Reference	Colonoscopy	Colonoscopy	Colonoscopy
							No screening	1373.9	22.7986*	Dominated			
							Annual FIT	833.6504	23.0001*	257.36			
							FIT+ colonoscopy for 50-year-old individuals	823.0024	23.0096*	335.21			
No screening							3020	18.6687*	15013				

Ladabaum and Mannelithara [24], 2016						Annual FIT	2407	18.7470*	-1177333									
						Biennial FIT	2211	18.7410*	436000									
						3-year MT-sDNA	5190	18.7423*	Dominated									
Barzi <i>et al.</i> [25], 2017	Markov model	US	LY	46-63	50-75	10-year colonoscopy	2861	15.227	Reference	Colonoscopy	Colonoscopy	Colonoscopy						
						Annual gFOBT	3164	15.215	Dominated									
						Biennial gFOBT	3054	15.218	Dominated									
						Annual FIT	3303	15.211	Dominated									
						Biennial FIT	3186	15.215	Dominated									
						10-year CTC	3062	15.225	Dominated									
						Annual stool DNA	4296	15.216	Dominated									
						Biennial stool DNA	4161	15.219	Dominated									
						Peterse <i>et al.</i> [26], 2021	Microsimulation	US	QALY	100	50-75	10-year colonoscopy	7751	0.209	Reference			Colonoscopy
												No screening	7286	0	Dominated			
Annual FIT	6793	0.189	47900															
5-year CTC	7479	0.177	8500															
Biennial <sup>m</sup> SEPT9	8298	0.175	Dominated															
Annual <sup>m</sup> SEPT9	8574	0.194	Dominated															
10-year PillCam	8951	0.165	Dominated															
5-year PillCam	9940	0.196	Dominated															
3-yearly MT-sDNA	8887	0.175	Dominated															
Annual MT-sDNA	10798	0.205	Dominated															

\*The exchange rate was €1 for \$1.13. \*\*The exchange rate was ¥1 for \$0.0088. Annual FIT for ages 50-54 and then biennial FIT for ages 55-75. CCE: Colon capsule endoscopy; CRC-SPIN: colorectal cancer simulated population model for incidence and natural history; CTC: computed tomographic colonography; DoD: department of defense; FIT: fecal immunochemical test; FS: sigmoidoscopy; gFOBT: guaiac FOBT; ICER: incremental cost-effectiveness ratio; LY: life-years; MISCAN: microsimulation screening analysis; <sup>m</sup>SEPT9: methylated Septin 9 DNA; MT-sDNA: multitarget stool DNA; NCTC: national CT colonography trial; QALY: quality-adjusted life-years; SimCRC: simulation model of colorectal cancer; CRC: colorectal cancer.

Ladabaum *et al.* [21] also compared 10-year colonoscopy with blood-based screening using the methylated septin 9 DNA (mSEPT9) test. Compared with colonoscopy every 10 years, annual <sup>m</sup>SEPT9-based strategies cost more and were less effective with fewer QALYs gained. Biennial <sup>m</sup>SEPT9-based strategies were cost-effective compared with colonoscopy every ten years, but the ICER was \$167,570-975,788 per QALY gained. Multitarget stool DNA (MT-sDNA)

every three years was approved by the US Food and Drug Administration (FDA) in 2014<sup>[28]</sup>. Although the sensitivity of MT-sDNA for CRC was 92.3%, which was much higher than that for FIT, the specificity of MT-sDNA was lower than that of FIT, resulting in an increased demand for colonoscopy and reducing its cost-effectiveness<sup>[29]</sup>. Another study by Ladabaum *et al.*<sup>[24]</sup> showed that, compared with 10-year colonoscopy, 3-year MT-sDNA was more expensive with fewer QALYs gained. In Peterse's study, compared with colonoscopy every 10 years, <sup>m</sup>SEPT9 (annual/biennial) and MT-sDNA (annual/3-year) cost more and were less effective with fewer QALYs gained<sup>[26]</sup>.

Virtual colonography with computed tomography colonography (CTC) or MR colonography (MRC) is another noninvasive approach that can potentially be an alternative examination for subjects for whom colonoscopy is not feasible or where colonoscopy capacity or manpower is constrained. Four studies showed that 10-year colonoscopy was more effective and less costly than CTC<sup>[16,18,25]</sup>. One study showed that 5-year CTC was less cost-effective than 10-year colonoscopy and displayed an ICER of \$372,727 per LY gained<sup>[17]</sup>, and another study displayed an ICER of \$8500 per QALY gained<sup>[26]</sup>. Notably, in these five studies, the same compliance rates for CTC and colonoscopy were assumed. Nevertheless, concerns have been raised about CTC because of the potential radiation risks, especially the risk of radiation-related cancer, and the compliance regarding CTC by the public in Asia is rarely reported<sup>[30,31]</sup>. The compliance rate for CTC may affect screening uptake and overall effectiveness.

Different age groups are associated with different risks of CRC. Precision screening strategies based on different CRC risks are important issues for balancing between effectiveness and usage of relevant resources. Ladabaum *et al.*<sup>[21]</sup> compared 10-year colonoscopy, a hybrid strategy with FIT years for ages 50-54 and then colonoscopy starting at age 55 (FIT/COLO 55,65), and a hybrid strategy with FIT years for ages 50-59 and then colonoscopy starting at age 60 (FIT/COLO 60,70). The FIT/COLO 55,65 hybrid strategy was the most effective strategy, followed by FIT and FIT/COLO 60,70 hybrid strategy. At a willingness-to-pay threshold of €50,000 per QALY gained, the FIT/COLO 55,65 hybrid strategy was the optimal strategy. These results reveal that a hybrid strategy with FIT and colonoscopy based on the different CRC risks was a cost-effective approach. Dan *et al.*<sup>[18]</sup> reported that a hybrid strategy using FIT for lower-risk patients aged 50-60 years and colonoscopy from ages 60 to 72 years showed it is potentially the most cost-effective strategy. It saves almost as many lives as 10-year colonoscopy but reduces costs by 25% and the number of colonoscopies and screening-related deaths by 35%. These results show that the hybrid strategy with FIT and colonoscopy based on the different risks for CRC was cost-effective. However, there was no relevant cost-effectiveness analysis for the precision screening strategies by the combination of age and other risk factors, and further studies are needed.

The optimal strategies at different WTP levels are shown in [Table 1](#). Two models from the US<sup>[16,25]</sup> and one model from Canada<sup>[15]</sup> reported that the optimal strategy was 10-year colonoscopy even at the threshold of \$20,000. One model from Japan reported the same results, which may be due to the much lower fee per colonoscopy in Japan than in the US or other countries<sup>[23]</sup>. Two modeling studies from the US and Singapore reported that the optimal strategy was 10-year colonoscopy at the threshold of \$100,000<sup>[18,26]</sup>. Three models from the US, Hong Kong, and France, however, reported that annual or biennial FIT screening strategies were optimal strategies at the threshold of \$50,000<sup>[17,22,24]</sup>.

Therefore, there is no “most recommended” test over the others at this time because the optimal strategy may vary along with the healthcare scenario, medical resources and expenses in individual countries, the WTP threshold of the healthcare payer, and local epidemiology of colorectal neoplasms collectively affect the choice of screening strategies. According to Dan's study, the cost of colonoscopy and the incidence of



CRC were the essential parameters for determining the optimal strategy. When the cost of colonoscopy was less than \$300, regardless of the risk of CRC, the strategy of 10-year colonoscopy was the most cost-effective<sup>[18]</sup>. When the cost of colonoscopy was above \$300, FIT was considered the dominant technique at lower incidence levels of CRC. At a higher WTP threshold, the strategy of 10-year colonoscopy was the most effective but required a huge budget and extensive logistic resources.

The quality of colonoscopy also largely impacts the effectiveness of the screening. The adenoma detection rate (ADR), the proportion of subjects with neoplastic lesions detected by colonoscopy among all subjects who undergo colonoscopy, is associated with the risk of incident CRC or CRC death and has been recommended as a key quality benchmark of colonoscopy<sup>[32-34]</sup>. Hassan *et al.*<sup>[35]</sup> reported that colonoscopies performed by endoscopists with low ADRs resulted in a 7% absolute reduction in the CRC incidence prevention rate compared to colonoscopies performed by those with an average ADR (70% vs. 77%). The difference in CRC incidence prevention rate increased to 21% when comparing endoscopists with an average ADR to those with a high ADR. The substantial reduction in the long-term colorectal cancer prevention rate also resulted in substantial losses in LY and economic resources<sup>[35]</sup>.

Cost-effectiveness studies have also compared different scenarios of repeat screening. Greuter *et al.*<sup>[36]</sup> reported that virtual colonography as CTC and MRC with more than three screening rounds were cost-effective alternatives for colonoscopy screening. Five rounds of CTC screening were even more effective at lower costs, and the ICER of five rounds of MRC was €3498 per LY gained compared with three rounds of colonoscopy<sup>[36]</sup>. In Aronsson's study, repeated colonoscopic screening strategies were more cost-effective than FIT when lifelong effects and costs were considered<sup>[37]</sup>. Therefore, although a single screening colonoscopy yielded the lowest cost per QALY, 10-year colonoscopy gained additional QALYs at a reasonable cost.

## **COST-EFFECTIVENESS ANALYSES OF DIFFERENT COLONOSCOPIC TREATMENT STRATEGIES FOR SMALL ADENOMA**

A substantial cost of a CRC screening program is represented by endoscopic polypectomy. Furthermore, polypectomy costs are partially related to the cost of pathologic examination. The cost-effectiveness analysis in this regard mainly relates to the “resect-and-discard” strategy<sup>[38]</sup>. The rationale for the resect-and-discard strategy is based on the low prevalence of advanced histology in small ( $\leq 1$  cm) adenomas, and discarding the specimen without sending it for pathological inspection could substantially reduce the cost. In the colonoscopy-based screening program, Lieberman *et al.*<sup>[39]</sup> reported that the proportions of patients in a screening cohort with advanced histology were only 1.7% in the 1-5 mm group and 6.6% in the 6-9 mm group. Gupta *et al.*<sup>[40]</sup> also reported that only 0.7% and 0.9% of polyps < 6 mm in size in the right and left colon were advanced neoplasms, respectively.

Image-enhanced endoscopy, such as narrow-band imaging (NBI), outperforms conventional white light colonoscopy in discriminating adenomatous from non-adenomatous colonic polyps with high accuracy<sup>[41]</sup>. In patients with small polyps (< 10 mm), the application of NBI and the resect-and-discard strategy might correctly guide post-polypectomy surveillance intervals without histopathology information. The American Society for Gastrointestinal Endoscopy (ASGE) developed the Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) initiative that has set the thresholds for real-time endoscopic assessment of the histology of diminutive colorectal polyps<sup>[41]</sup>. The threshold in the PIVI document regarding the application of the resect-and-discard strategy for colorectal polyps < 5 mm in size is that endoscopic technology should provide at least 90% agreement in the assignment of the appropriate post-polypectomy surveillance interval. In this context, according to Hassan's study, the application of the resect-and-discard

strategy for diminutive polyps resulted in a savings of \$25/person without reducing the screening efficacy. This approach would result in undiscounted annual savings of \$33 million for the US population<sup>[38]</sup>. However, due to the thresholds in the PIVI document being at least 90% in agreement in the assignment of the appropriate post-polypectomy surveillance interval, whether each endoscopy achieves the thresholds with high confidence is still unclear. As Patel *et al.*<sup>[42]</sup> reported, previous studies revealed a discrepancy in agreement in surveillance intervals between endoscopists at academic centers and community-based endoscopists. This discrepancy may hinder the applicability of the resect-and-discard strategy and make its cost-effectiveness uncertain. Whether the aforementioned resect-and-discard strategy is similarly applicable to FIT-positive colonoscopy is not clear because the distributions of size and advanced histology of detected adenomas in the FIT-positive population are largely different from the screening colonoscopy cohort (general population of screening age). Hsu *et al.*<sup>[43]</sup> analyzed 3920 neoplastic lesions in a FIT-positive colonoscopy cohort and compared them with 9789 neoplastic lesions in a direct screening colonoscopy cohort. Subjects who underwent colonoscopy for positive FIT had a lower prevalence of diminutive polyps (32.2%) than that in the screening colonoscopy cohort (60.5%); therefore, the resect-and-discard strategy in FIT-colonoscopy may not result in a similar degree of cost reduction that observed in the colonoscopy-based screening strategy. Although FIT positivity is associated with an increased likelihood of detecting neoplasms with advanced histology, those diminutive adenomas being detected in FIT-positive subjects were associated with a low risk of advanced histology (4.3%), and none of these patients had invasive cancer; hence, the risk of exposing the patient to undertreatment of invasive cancer by the resect-and-discard strategy is nearly zero. Moreover, compared with histopathological assessment, the agreement in determining surveillance interval by applying the resect-and-discard strategy was as high as 96.5%. Collectively, the resect-and-discard strategy for diminutive polyps in FIT-colonoscopy is feasible and could still save substantial costs making it a cost-effective approach.

## **COST-EFFECTIVENESS ANALYSIS OF COLONOSCOPIC TREATMENT STRATEGIES FOR LARGE NEOPLASMS**

The cost-effectiveness analyses on colonoscopic treatment for large colorectal neoplasms mainly pertain to large flat lesions - laterally spreading tumors (LSTs). The LST was originally proposed by Kudo for tumors that spread extensively and circumferentially along the colonic wall and are larger than 10 mm in diameter<sup>[44,45]</sup>. EMR is a useful therapeutic technique for LST; however, the maximum diameter of the lesion for en bloc resection is approximately 20 mm, owing to the size of the snare, the technical difficulty, and the perforation risk<sup>[46]</sup>. For LSTs larger than 20 mm, the piecemeal EMR (pEMR) technique is commonly used, but it may be associated with a higher risk of recurrence<sup>[47-49]</sup>. In Yamada's study, LSTs with the presence of a large nodule, a depression, and an invasive pit pattern under magnified chromoendoscopy had a higher risk of deep submucosal invasion<sup>[50]</sup>. Due to the substantial risk of submucosal invasion and multifocal invasion, en bloc resection with ESD techniques could be reserved for some specific lesions as an alternative procedure to more invasive surgery<sup>[51]</sup>. Universal treatment with ESD for all LSTs larger than 20 mm may not be cost-effective because of its technical difficulty with a long procedure time, higher cost for the devices, and higher risk of perforation complications. In Bahin's study, the cost-effectiveness of three strategies for removing large LSTs > 20 mm was compared: (1) wide-field endoscopic mucosal resection (WF-EMR); (2) universal endoscopic submucosal dissection (U-ESD); and (3) selective ESD (S-ESD)<sup>[52]</sup>. In the WF-EMR strategy, lesions classified as highly suspicious for submucosal invasive cancer (SMIC) were referred for surgical management, suspicious rectal lesions classified as low-risk SMIC were referred for transanal excision, and all other lesions were treated via WF-EMR. In the U-ESD strategy, all lesions were initially treated by ESD regardless of SMIC suspicion. In the S-ESD strategy, lesions with high suspicion for SMIC were treated with ESD; others were treated with WF-EMR. S-ESD was the least expensive strategy and more effective than WF-EMR by preventing 19 additional surgeries per 1000 patients. Compared with

S-ESD, U-ESD prevented another 13 surgeries at an incremental cost per surgery of \$210,112<sup>[52]</sup>. Therefore, S-ESD is the preferred treatment strategy for large LSTs [Table 2].

LSTs are macroscopically classified into granular (LST-G) and nongranular types (LST-NG). LST-G is further subclassified into homogeneous (LST-G-H) and nodular mixed (LST-G-M) types. LST-NG is further subclassified into flat elevated (LST-NG-F) and pseudo-depressed (LST-NG-PD) types. Such a classification is clinicopathologically relevant, and one meta-analysis showed that LST-NG-PD had an extraordinarily higher risk of SMIC (31.6%) than LST-NG-FE (4.9%), LST-G-H (0.5%), and LST-G-NM (10.5%), and SMIC was more common in distally located LSTs than in proximally located LSTs (odds ratio: 2.50; 95%CI: 1.24-5.02)<sup>[53]</sup>. Sekiguchi *et al.*<sup>[54]</sup> reported that, for colon/rectal LST-NG  $\geq 2$  cm and LST-G-M  $\geq 3$  cm, when compared with pEMR, ESD was more cost-effective with a higher cost that was offset by fewer recurrences and surgeries. The ICERs for avoided recurrence and surgery for ESD against pEMR were \$3575-4521 and \$69,604-77,689, respectively. The probability of ESD being chosen as a more cost-effective option than pEMR was  $> 50\%$  at willingness-to-pay values of  $\geq \$3795-4744$  for avoiding recurrence and  $\geq \$90,143-99,631$  for avoiding surgery<sup>[53]</sup>. Due to the higher cost of ESD, whether the ESD strategy is cost-effective depends not only on cost settings but also on the skill level of the endoscopist, which largely affects the time cost of ESD as well as the WTP value for avoiding recurrence/surgery. Further study is warranted.

## COST-EFFECTIVENESS ANALYSES OF DIFFERENT COLONOSCOPIC SURVEILLANCE STRATEGIES

Determination of the surveillance interval after colonoscopy is currently based on the risk level as determined by colonoscopic findings<sup>[5]</sup>. Sonnenberg's study reported that the most common reason for performing colonoscopy is surveillance of previously discovered colorectal neoplasia, either adenoma or cancer<sup>[8]</sup>. Five studies assessed the cost-effectiveness of colonoscopic surveillance strategies with different surveillance intervals in patients with adenomas [Table 3]<sup>[55-59]</sup>. Four studies reported that, compared with no surveillance strategy, colonoscopic surveillance strategies were more costly but had more LY/QALY gain, making them more cost-effective strategies<sup>[55-58]</sup>. Only one study showed that colonoscopic surveillance strategies were less costly with more QALY gain<sup>[59]</sup>. In Arguedas' study, colonoscopic surveillance every three years for patients with large adenoma and five years for patients with small adenoma or without adenoma were cost-effective and had an ICER of \$27,970 per LY gained compared to no surveillance<sup>[55]</sup>. Shaukat *et al.*<sup>[56]</sup> also reported that colonoscopy surveillance every three years for patients with large adenoma and every five years for patients with small adenoma or without adenoma was cost-effective and had an ICER of \$20,600 per LY gained. Saini *et al.*<sup>[58]</sup> found that, compared with no surveillance (colonoscopy every 10 years for patients with any endoscopic finding), the strategy of colonoscopy surveillance every 3 years for high-risk patients and 10 years for low-risk patients was highly cost-effective, with an ICER of \$5743 per QALY gained. In contrast, the strategy of colonoscopic surveillance every three years for high-risk patients and five years for low-risk patients was relatively expensive, with an ICER of \$296,266 per QALY gain. The strategy of colonoscopy surveillance every three years for all patients only resulted in additional cost and harm. Hassan *et al.*<sup>[57]</sup> simulated 60-year-old patients with adenoma and found that single colonoscopy surveillance after one year was cost-effective, with an ICER of \$66,136 per LY gained. These results reveal the relatively high prevalence of CRC one year after clearing polypectomy and a relative deficiency of the current guidelines to exclude a clinically meaningful risk of CRC after polypectomy<sup>[57]</sup>. Meester *et al.*<sup>[59]</sup> conducted a cost-effectiveness analysis of different screening strategies. In patients with low-risk adenomas in the FIT screening program, the risk of CRC incidence and mortality was higher than those with LRAs in the colonoscopy screening program. Thus, the cost-effectiveness ratio for high-intensity surveillance (5 years) versus low-intensity surveillance (10 years) was more favorable (ICER = \$11,100 per QALY gained) than in patients with low-risk adenomas in the colonoscopy screening program.

**Table 2. Overview of the cost-effectiveness analyses of the different endoscopic treatment strategies for LST**

Study	Country	Effectiveness measurement	Patients	Treatment strategies	Cost (\$)	Effectiveness	ICER
Bahin <i>et al.</i> <sup>[52]</sup> , 2017	Australia	Number of surgeries avoided	laterally spreading colorectal lesions (LSLs) > 20 mm	Selective ESD	4224 per 1000 cases	925 surgeries avoided	Reference
				WF-EMR	4335 per 1000 cases	906 surgeries avoided	Dominated
				Universal ESD	6912	938 surgeries avoided	210112
Sekiguchi <i>et al.</i> <sup>[54]</sup> , 2021	Japan	An avoid recurrence/an avoid surgery	Colonic LST-NG $\geq 2$ cm	pEMR	1948	-	Reference
				ESD	2834	NNB by preventing a recurrence: 4/NNB by preventing a surgery: 78.7	3575/69604
			Rectal LST-NG $\geq 2$ cm	pEMR	3555	-	Reference
				ESD	4469	NNB by preventing a recurrence: 4.9/NNB by preventing a surgery: 84.7	4521/77689
			Colonic LST-G-M $\geq 3$ cm	pEMR	2042	-	Reference
				ESD	2969	NNB by preventing a recurrence: 4.2/NNB by preventing a surgery: 82	3883/76118
	Swedish	An avoid recurrence/an avoid surgery	Colonic LST-NG $\geq 2$ cm	pEMR	5335	-	Reference
				ESD	3438	-	Dominant
			Rectal LST-NG $\geq 2$ cm	pEMR	9682	-	Reference
				ESD	8609	-	Dominant
			Colonic LST-G-M $\geq 3$ cm	pEMR	5495	-	Reference
				ESD	3780	-	Dominant
Rectal LST-G-M $\geq 3$ cm	pEMR	7890	-	Reference			
	ESD	6878	-	Dominant			

EMR: Endoscopic mucosal resection; ESD: endoscopic submucosal dissection; ICER: incremental cost-effectiveness ratio; LST: laterally spreading tumor; LST-G-M: laterally spreading tumor with nodular mixed types; LST-NG: laterally spreading tumor with nongranular types; pEMR: piecemeal endoscopic mucosal resection; WF-EMR: wide-field endoscopic mucosal resection.

However, the overall risk and benefit of surveillance in patients with high-risk adenomas in the FIT screening program versus in the colonoscopy screening program were similar. The ICERs for high-intensity surveillance (three years) versus low-intensity surveillance for patients with high-risk adenomas were similar (\$11,100 per QALY gained) in the FIT and colonoscopy screening programs<sup>[59]</sup>.

Recent studies have shown the usefulness of using FIT in detecting advanced neoplasms during colonoscopic surveillance intervals. For example, Cross *et al.*<sup>[60]</sup> reported that in intermediate-risk patients (with three to four adenomas < 10 mm or at least one  $\geq 10$  mm), the cumulative sensitivity and specificity for CRC of three rounds of annual FIT with low threshold levels for fecal hemoglobin (10  $\mu\text{g/g}$ ) were 91.7% (95%CI: 73.0-99.0) and 69.8% (95%CI: 68.5-71.1), respectively. However, in this study, the three-year program sensitivities for CRC and advanced adenomas of annual FIT at the threshold level of 10  $\mu\text{g/g}$  were 72% and 57%, respectively. This strategy would result in 28% of CRCs and 43% of advanced adenomas being missed compared with three-year colonoscopic surveillance<sup>[60]</sup>. A recent study by Peng *et al.*<sup>[61]</sup> from the Taiwan CRC Screening Program revealed that those who received subsequent FIT after negative colonoscopy had a significantly lower risk of incident CRCs than those who did not, which was assumed to be mainly

**Table 3. Overview of the cost-effectiveness analyses on different colonoscopic surveillance strategies**

Study	Model type	Country	Effectiveness	Participants	Screening strategy	Surveillance strategy	Cost per person	LY/QALY	ICER	
Arguedas <i>et al.</i> <sup>[55]</sup> , 2001	Markov model	US	LY	50-year-old patients with adenomas		No surveillance	1014	8.45	Reference	
						Colonoscopy 3 years than 5 years	1572	8.48	27970	
						Celecoxib	11503	8.49	1715199	
Shaukat <i>et al.</i> <sup>[56]</sup> , 2009	Markov model	US	LY	50-year-old patients with adenomas		No surveillance	2796	18.64	Reference	
						Colonoscopy 3 years for large adenoma, 5 years for small or no adenoma	4579	18.72	20600	
Hassan <i>et al.</i> <sup>[57]</sup> , 2009	Simple decision tree	Italy	LY	60-year-old patients with adenomas		No surveillance	-	-	Reference	
						Colonoscopy after 1 year	-	-	66136	
Saini <i>et al.</i> <sup>[58]</sup> , 2010	Markov model	US	QALY	50-year-old patients with adenomas		No surveillance	1775	17.57	Reference	
						Colonoscopy 3 years for HR, 10 years for LR	1831	17.58	5734	
						Colonoscopy 3 years for HR, 5 years for LR	3170	17.58	296266	
						Colonoscopy 3 years for HR, and LR	4936	17.58	316100	
Meester <i>et al.</i> <sup>[59]</sup> , 2019	Microsimulation	US	QALY	50-year-old patients with LRA	Colonoscopy	No Surveillance	4110	19.456	Dominated	
						Colonoscopy after 10 years	3870	19.570	Reference	
						Colonoscopy 10 years for LR, 5 years for HR	3898	19.577	4000	
						Colonoscopy 5 years for LR, 3 years for HR	4290	19.589	18400	
						FIT	No Surveillance	4699	19.407	Dominated
							Colonoscopy after 10 years	4536	19.510	Dominated
							Colonoscopy 10 years for LR, 5 years for HR	4454	19.530	Reference
				50-year-old patients with HRA	Colonoscopy	Colonoscopy 5 years for LR, 3 years for HR	4841	19.565	11100	
						No Surveillance	6622	19.303	Dominated	
						Colonoscopy after 10 years	5633	19.491	Reference	
						Colonoscopy 10 years for LR, 5 years for HR	5784	19.525	4500	
						Colonoscopy 5 years for LR, 3 years for HR	6052	19.557	8400	
						FIT	No Surveillance	6608	19.302	Dominated
							Colonoscopy after 10 years	6113	19.462	Dominated
Colonoscopy 10 years for LR, 5 years for HR	5856	19.520	Reference							
Colonoscopy 5	6131	19.553	8400							

years for LR, 3  
years for HR

FIT: Fecal immunochemical test; HRA: high-risk adenoma; ICER: incremental cost-effectiveness ratio; LRA: low-risk adenoma; LY: life-years; QALY: quality-adjusted life-years.

attributable to the detection of noncancerous advanced adenoma that might have been missed at the initial colonoscopy. Whether such an “interval-FIT” approach could become a cost-effective alternative or an adjunctive approach to colonoscopic surveillance is largely unknown and requires further study.


## EMERGING ISSUES THAT REQUIRE FURTHER EXPLORATION

Although colonoscopy and related procedures are cost-effective for CRC screening and post-polypectomy surveillance, there are still some issues that require further exploration [Table 4]. First, the application of new technologies such as artificial intelligence (AI) in colonoscopy is now attracting substantial attention, and its cost-effectiveness is worthy of investigation<sup>[62]</sup>. The major roles of CAD during colonoscopy include computer-aided detection (CADe) and computer-aided characterization (CADx)<sup>[63]</sup>. CADe helps endoscopists detect polyps that could be overlooked visually, and CADx improves accurate characterization by optical biopsy<sup>[63]</sup>. Mori *et al.*<sup>[64]</sup> demonstrated that the use of AI enabled the “diagnose-and-leave” strategy and resulted in substantial cost reductions for colonoscopy compared with the resect-all-polyps strategy. However, there remains no comprehensive cost-effectiveness analysis conducted for the application of AI in colonoscopy. This is because this technology is still in its primitive stage, and many clinical and cost parameters remain unclear. For example, AI tools can increase the detection of small adenoma, and it may result in a substantial increment in the pathologic examination cost. Moreover, it remains unclear for which level of endoscopists AI is most beneficial; therefore, using universal ADR parameters may lead to an erroneous conclusion. Further study is anticipated. Second, exploration of the cost-effectiveness of CRC screening with different strategies in young (40-49 years) adults is an emerging issue due to the increasing incidence of young-onset CRC in many countries<sup>[65,66]</sup>. According to the recent modeling study by the US Preventive Services Task Force, if screening were to begin at age 45 years instead of age 50, the models of CRC screening strategies with stool tests, colonoscopy, or CTC showed 22-27 additional LY gained (8%-9% increase) and required 161-784 additional colonoscopies (10%-23% increase) per 1000 persons, and these results suggest that CRC screening starting at age 45 years provides an efficient balance of colonoscopy burden and life-years gained<sup>[67]</sup>. Given the different young-onset CRC epidemiology and the healthcare facts across different countries, further cost-effectiveness analysis studies based on local scenarios are needed. Third, omics technology has provided integrated proteogenomic analysis for precision medicine, especially for cancer prevention. Targeted population screening for CRC would reduce the burden and demand for colonoscopy<sup>[68]</sup>. Comprehensive assessment of the risk of CRC and the development of reliable and verifiable risk stratification tools that can be used in the clinic are essential. Three studies reported that the current uniform colonoscopy screening strategy appeared more cost-effective than personalized risk-based screening strategies based on polygenic risk profile and family history<sup>[69-71]</sup>. However, cost-effectiveness is highly dependent on the costs of determining risk, and such costs may decrease in the future along with the further advance of omic technologies. Furthermore, cost-effectiveness analysis studies for personalized CRC screening with different strategies are needed. Fourth, endoscopic full-thickness resection (EFTR) has been demonstrated to be effective and safe for non-lifting and difficult lesions<sup>[72]</sup>. Only one cost-effectiveness analysis study reported that the mean costs per R0 resection were €3708.98 for EFTR, €3115.10 for standard endoscopic resection, and €8924.05 for surgical treatment. EFTR is cost-effective in comparison with surgical and endoscopic treatment for colonic non-lifting and difficult lesions<sup>[73]</sup>. Moreover, long-term follow-up is also needed to further assess the cost-effectiveness of EFTR. Fifth, many assumptions in the cost-effectiveness analyses limit the validity of those studies. For example, colonoscopy quality or skill level

**Table 4. Emerging cost-effectiveness issues that are worthwhile to investigate**

Potential cost-effectiveness issues
• Application of AI in colonoscopy: CAdE and CAdx
• EFTR for difficult colonic lesions
• ESD vs. pEMR for large colorectal neoplasms (i.e., LST) at different endoscopist skill levels and payment levels
• CRC screening with different strategies for young (40–49 years) adults
• Endoscopic vs. surgery for superficial T1 CRC
• Noninvasive tests (FIT, MT-sDNA, etc.) vs. colonoscopy as the surveillance tool
• Noninvasive tests (FIT, MT-sDNA, etc.) vs. colonoscopy as the screening tool for subjects with a family history of CRC

AI: Artificial intelligence; CRC: colorectal cancer; EFTR: endoscopic full-thickness resection; FIT: fecal immunochemical test; CAdE: computer-aided detection; CAdx: computer-aided characterization; ESD: endoscopic submucosal dissection; pEMR: piecemeal endoscopic mucosal resection; LST: laterally spreading tumor; MT-sDNA: multitarget stool DNA.



**Figure 1.** Payment of colonoscopy worldwide in 2020.

of endoscopic diagnosis (ability to accurately diagnose neoplasms and estimate invasion depth) or treatment such as polypectomy/EMR/ESD by individual endoscopists were assumed to be consistent in most of the cost-effectiveness models. Furthermore, the payment for colonoscopy varies greatly from country to country and ranges from \$45.2 to \$1695. Colonoscopy payments tend to be higher in countries with higher gross domestic products (GDPs) per capita, but a significant discrepancy still exists even within the same category of GDP level [Figure 1 and Supplementary Table 1], which has a significant impact on the results of cost-effectiveness analyses and the optimal strategies. When the payment for colonoscopy is low, colonoscopy-based screening or more frequent surveillance strategies will become the dominant or more cost-effective strategy over other noninvasive or less intensive strategies. More comprehensive cost-effectiveness analysis studies that take into account the diversity of neoplasms, heterogeneity of the clinical practice scenario, or the existing comorbidities of the patients are needed.

## CONCLUSIONS

Gaps between limited healthcare resources and expanding healthcare service demands, and the development of new technologies have become a significant pressure on many healthcare systems worldwide and generate the demand for comprehensive health technology assessment, including economic appraisals, for scientific policymaking. Our current review provides updates on the economic appraisal of colonoscopic practices and their related procedures in the context of population CRC screening and surveillance. Many of the cost-effective strategies have been implemented in our current practice, but some have not, which may be due to the insufficient diversity being accommodated in the parameters or assumptions used in the analyses and the limited number of high-quality studies or clinical trials from which parameters were derived. Finally, whether a cost-effective strategy is applicable to the individual program still needs careful and specific consideration, which must include the healthcare context and the availability of certain services in the individual countries or healthcare systems, patient preference, and WTP levels.

## DECLARATIONS

### Authors' contributions

Concept and design of the article: Chiu HM

Literature review: Hsu WF

Drafting of the manuscript: Hsu WF, Chiu HM

### Availability of data and materials

Not applicable.

### Financial support and sponsorship

This study was partially supported by the Health Promotion Administration, Ministry of Health and Welfare. (A1091116).

### Conflicts of interest

Both authors have no conflict of interest to be declared regarding this manuscript.

### Ethical approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Copyright

© The Author(s) 2022.

## REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209-49. DOI PubMed
2. Chiu HM, Jen GH, Wang YW, et al. Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers. *Gut* 2021;70:2321-9. DOI PubMed PMC
3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of Colorectal Cancer by Colonoscopic Polypectomy. *N Engl J Med* 1993;329:1977-81. DOI PubMed
4. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med* 2012;366:687-96. DOI PubMed PMC
5. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the us multi-society task force on colorectal cancer. *Gastrointest Endosc* 2020;91:463-485.e5. DOI PubMed PMC



6. Rutter MD, East J, Rees CJ, et al. British society of gastroenterology/association of coloproctology of great Britain and Ireland/public health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. *Gut* 2020;69:201-23. DOI PubMed PMC
7. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: european society of gastrointestinal endoscopy (ESGE) guideline - update 2020. *Endoscopy* 2020;52:687-700. DOI PubMed
8. Sonnenberg A, Amorosi SL, Lacey MJ, Lieberman DA. Patterns of endoscopy in the United States: analysis of data from the centers for medicare and medicaid services and the national endoscopic database. *Gastrointest Endosc* 2008;67:489-96. DOI PubMed
9. Harewood G. Colonoscopy practice patterns since introduction of medicare coverage for average-risk screening. *Clinical Gastroenterology and Hepatology* 2004;2:72-7. DOI PubMed
10. Moher D, Shamseer L, Clarke M, et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. DOI PubMed PMC
11. Higgins J, Thomas J. Cochrane handbook for systematic reviews of interventions. Available from: <https://training.cochrane.org/handbook/current> [Last accessed on 20 Apr 2022].
12. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. preventive services task force. *Ann Intern Med* 2002;137:96-104. DOI PubMed
13. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. *Epidemiol Rev* 2011;33:88-100. DOI PubMed PMC
14. Quintero E, Castells A, Bujanda L, et al; COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. *N Engl J Med* 2012;366:697-706. DOI PubMed
15. Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. *CMAJ* 2010;182:1307-13. DOI PubMed PMC
16. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. *J Natl Cancer Inst* 2010;102:1238-52. DOI PubMed PMC
17. Hassan C, Benamouzig R, Spada C, et al. Cost effectiveness and projected national impact of colorectal cancer screening in France. *Endoscopy* 2011;43:780-93. DOI PubMed
18. Dan YY, Chuah BY, Koh DC, Yeoh KG. Screening based on risk for colorectal cancer is the most cost-effective approach. *Clin Gastroenterol Hepatol* 2012;10:266-71.e1. DOI PubMed
19. Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. *Clin Gastroenterol Hepatol* 2013;11:1158-66. DOI PubMed
20. Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. *Am J Gastroenterol* 2013;108:120-32. DOI PubMed
21. Ladabaum U, Alvarez-Osorio L, Rösch T, Brueggenjuergen B. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA. *Endosc Int Open* 2014;2:E96-E104. DOI PubMed PMC
22. Wong CK, Lam CL, Wan YF, Fong DY. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing. *BMC Cancer* 2015;15:705. DOI PubMed PMC
23. Sekiguchi M, Igarashi A, Matsuda T, et al. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data. *Jpn J Clin Oncol* 2016;46:116-25. DOI PubMed
24. Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. *Gastroenterology* 2016;151:427-439.e6. DOI PubMed
25. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. *Cancer* 2017;123:1516-27. DOI PubMed PMC
26. Peterse EFP, Meester RGS, de Jonge L, et al. Comparing the cost-effectiveness of innovative colorectal cancer screening tests. *J Natl Cancer Inst* 2021;113:154-61. DOI PubMed PMC
27. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. *Cancer* 2006;107:2152-9. DOI PubMed
28. Jaklevic MC. Pandemic spotlights in-home colon cancer screening tests. *JAMA* 2020. DOI PubMed
29. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med* 2014;370:1287-97. DOI PubMed
30. Neri E, Faggioni L, Cerri F, et al. CT colonography versus double-contrast barium enema for screening of colorectal cancer: comparison of radiation burden. *Abdom Imaging* 2010;35:596-601. DOI PubMed
31. Hirofuji Y, Aoyama T, Koyama S, Kawaura C, Fujii K. Evaluation of patient dose for barium enemas and CT colonography in Japan. *Br J Radiol* 2009;82:219-27. DOI PubMed
32. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. *Gastrointest Endosc* 2015;81:31-53. DOI PubMed
33. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. *N Engl J Med* 2010;362:1795-803. DOI PubMed
34. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014;370:1298-306. DOI PubMed PMC

35. Hassan C, Rex DK, Zullo A, Kaminski MF. Efficacy and cost-effectiveness of screening colonoscopy according to the adenoma detection rate. *United European Gastroenterol J* 2015;3:200-7. DOI PubMed PMC
36. Greuter MJ, Berkhof J, Fijneman RJ, et al. The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. *Br J Radiol* 2016;89:20150910. DOI PubMed PMC
37. Aronsson M, Carlsson P, Levin LÅ, Hager J, Hultcrantz R. Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer. *Br J Surg* 2017;104:1078-86. DOI PubMed
38. Hassan C, Pickhardt PJ, Rex DK. A resect and discard strategy would improve cost-effectiveness of colorectal cancer screening. *Clin Gastroenterol Hepatol* 2010;8:865-9, 869.e1. DOI PubMed
39. Lieberman D, Moravec M, Holub J, Michaels L, Eisen G. Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. *Gastroenterology* 2008;135:1100-5. DOI PubMed PMC
40. Gupta N, Bansal A, Rao D, et al. Prevalence of advanced histological features in diminutive and small colon polyps. *Gastrointest Endosc* 2012;75:1022-30. DOI PubMed
41. Dayyeh BK, Thosani N, Konda V, et al; ASGE Technology Committee. ASGE technology committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps. *Gastrointest Endosc* 2015;81:502.e1-502.e16. DOI PubMed
42. Patel SG, Schoenfeld P, Kim HM, et al. Real-time characterization of diminutive colorectal polyp histology using narrow-band imaging: implications for the resect and discard strategy. *Gastroenterology* 2016;150:406-18. DOI PubMed PMC
43. Hsu WF, Cheng SY, Shun CT, et al. Higher risk of advanced histology in adenoma less than 10 mm in fecal immunochemical test screening: Implication for management. *J Gastroenterol Hepatol* 2020;35:1738-45. DOI PubMed
44. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. *Endoscopy* 1993;25:455-61. DOI PubMed
45. Kudo SE, Takemura O, Ohtsuka K. Flat and depressed types of early colorectal cancers: from East to West. *Gastrointest Endosc Clin N Am* 2008;18:581-93, xi. DOI PubMed
46. Tanaka S, Oka S, Kaneko I, et al. Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. *Gastrointest Endosc* 2007;66:100-7. DOI PubMed
47. Brooker JC, Saunders BP, Shah SG, Thapar CJ, Suzuki N, Williams CB. Treatment with argon plasma coagulation reduces recurrence after piecemeal resection of large sessile colonic polyps: a randomized trial and recommendations. *Gastrointest Endosc* 2002;55:371-5. DOI PubMed
48. Conio M, Repici A, Demarquay J, Bianchi S, Dumas R, Filiberti R. EMR of large sessile colorectal polyps. *Gastrointestinal Endoscopy* 2004;60:234-41. DOI PubMed
49. Horiki N, Omata F, Uemura M, et al. Risk for local recurrence of early gastric cancer treated with piecemeal endoscopic mucosal resection during a 10-year follow-up period. *Surg Endosc* 2012;26:72-8. DOI PubMed
50. Yamada M, Saito Y, Sakamoto T, et al. Endoscopic predictors of deep submucosal invasion in colorectal laterally spreading tumors. *Endoscopy* 2016;48:456-64. DOI PubMed
51. Gotoda T, Kondo H, Ono H, et al. A new endoscopic mucosal resection procedure using an insulation-tipped electrosurgical knife for rectal flat lesions: report of two cases. *Gastrointestinal Endoscopy* 1999;50:560-3. DOI PubMed
52. Bahin FF, Heitman SJ, Rasouli KN, et al. Wide-field endoscopic mucosal resection versus endoscopic submucosal dissection for laterally spreading colorectal lesions: a cost-effectiveness analysis. *Gut* 2018;67:1965-73. DOI PubMed
53. Bogie RMM, Veldman MHJ, Snijders LARS, et al. Endoscopic subtypes of colorectal laterally spreading tumors (LSTs) and the risk of submucosal invasion: a meta-analysis. *Endoscopy* 2018;50:263-82. DOI PubMed
54. Sekiguchi M, Igarashi A, Mizuguchi Y, et al. Cost-effectiveness analysis of endoscopic resection for colorectal laterally spreading tumors: Endoscopic submucosal dissection versus piecemeal endoscopic mucosal resection. *Dig Endosc* 2022;34:553-68. DOI PubMed
55. Arguedas MR, Heudebert GR, Wilcox CM. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. *Aliment Pharmacol Ther* 2001;15:631-8. DOI PubMed
56. Shaukat A, Parekh M, Lipscomb J, Ladabaum U. Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance? *Int J Technol Assess Health Care* 2009;25:222-31. DOI PubMed PMC
57. Hassan C, Pickhardt PJ, Di Giulio E, Kim DH, Zullo A, Morini S. Cost-effectiveness of early one-year colonoscopy surveillance after polypectomy. *Dis Colon Rectum* 2009;52:964-71; discussion 971. DOI PubMed
58. Saini SD, Schoenfeld P, Vijan S. Surveillance colonoscopy is cost-effective for patients with adenomas who are at high risk of colorectal cancer. *Gastroenterology* 2010;138:2292-9, 2299.e1. DOI PubMed
59. Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, Zauber AG, Knudsen AB, Ladabaum U. High-intensity versus low-intensity surveillance for patients with colorectal adenomas: a cost-effectiveness analysis. *Ann Intern Med* 2019;171:612-22. DOI PubMed PMC
60. Cross AJ, Wooldrage K, Robbins EC, et al. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. *Gut* 2019;68:1642-52. DOI PubMed PMC
61. Peng SM, Hsu WF, Wang YW, et al. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme. *Gut* 2021;70:1318-24. DOI PubMed PMC
62. Liedlgruber M, Uhl A. Computer-aided decision support systems for endoscopy in the gastrointestinal tract: a review. *IEEE Rev*

- Biomed Eng* 2011;4:73-88. DOI PubMed
63. Misawa M, Kudo SE, Mori Y, et al. Current status and future perspective on artificial intelligence for lower endoscopy. *Dig Endosc* 2021;33:273-84. DOI PubMed
  64. Mori Y, Kudo SE, East JE, et al. Cost savings in colonoscopy with artificial intelligence-aided polyp diagnosis: an add-on analysis of a clinical trial (with video). *Gastrointest Endosc* 2020;92:905-911.e1. DOI PubMed
  65. Vuik FE, Nieuwenburg SA, Bardou M, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. *Gut* 2019;68:1820-6. DOI PubMed PMC
  66. Howren A, Sayre EC, Loree JM, et al. Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: a population-based longitudinal study. *J Natl Cancer Inst* 2021;113:863-8. DOI PubMed PMC
  67. Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal cancer screening: an updated modeling study for the us preventive services task force. *JAMA* 2021;325:1998-2011. DOI PubMed PMC
  68. Kuipers EJ, Spaander MC. Personalized screening for colorectal cancer. *Nat Rev Gastroenterol Hepatol* 2018;15:391-2. DOI PubMed
  69. Cenin DR, Naber SK, de Weerd AC, et al. Cost-effectiveness of personalized screening for colorectal cancer based on polygenic risk and family history. *Cancer Epidemiol Biomarkers Prev* 2020;29:10-21. DOI PubMed PMC
  70. Sekiguchi M, Igarashi A, Sakamoto T, Saito Y, Esaki M, Matsuda T. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. *J Gastroenterol Hepatol* 2020;35:1555-61. DOI PubMed
  71. Naber SK, Kundu S, Kuntz KM, et al. Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk: current status and future potential. *JNCI Cancer Spectr* 2020;4:pkz086. DOI PubMed PMC
  72. Schmidt A, Beyna T, Schumacher B, et al. Colonoscopic full-thickness resection using an over-the-scope device: a prospective multicentre study in various indications. *Gut* 2018;67:1280-9. DOI PubMed
  73. Kuellmer A, Behn J, Beyna T, et al. Endoscopic full-thickness resection and its treatment alternatives in difficult-to-treat lesions of the lower gastrointestinal tract: a cost-effectiveness analysis. *BMJ Open Gastroenterol* 2020;7:e000449. DOI PubMed PMC